The research of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer patients
10.3760/cma.j.issn.0253-3766.2019.08.002
- VernacularTitle: 乳腺癌新辅助化疗后前哨淋巴结活检术研究进展
- Author:
Jieya ZOU
1
;
Xiaoqi WANG
;
Lifei SUN
;
Wenhuan WANG
;
Yue WANG
;
Jianyun NIE
Author Information
1. Department Of Second Breast Surgery, the third Affiliated Hospital of Kunming Medical University, Kunming 650118, China
- Publication Type:Review
- Keywords:
Breast neoplasms;
Neoadjuvant chemotherapy;
Sentinel lymph node biopsy
- From:
Chinese Journal of Oncology
2019;41(8):565-568
- CountryChina
- Language:Chinese
-
Abstract:
With the extensive use of sentinel lymph node biopsy (SLNB), some breast cancer patients could avoid axillary lymph node dissection (ALND) and its complications. Neoadjuvant chemotherapy plays an important role in the multimodality therapies of breast cancer. After neoadjuvant chemotherapy, some patients with breast cancer were down-staged from positive axillary lymph node (cN+ ) to clinically negative (cN0). For these patients, the feasibility and safety of sentinel lymph node biopsy remains controversial. However, with the application of new technologies, SLNB is expected to become the main treatment for breast cancer patients with stage cN0 after neoadjuvant chemotherapy.
